Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients

Grandi, Tarciana; Silva, Cláudia Maria Dornelles da; Amaral, Karine Medeiros; Picon, Paulo Dornelles; Costi, Cíntia; Fré, Nicole Nascimento da; Fiegenbaum, Marilu; Gregianini, Tatiana Schäffer; Niel, Christian; Rossetti, Maria Lúcia Rosa

doi:10.1590/0074-0276130372

Cited by 7 publications

(4 citation statements)

References 40 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 32 studies with a total of 5943 HCV cases (NR: 3380; SVR: 2563) and 2697 controls were included in the present study. 4 – 8 , 17 – 43 Included studies characteristics are summarized in Table 4 . Twenty-three studies were included for the rs1800896 (-1082 A/G) SNP, 4 – 8 , 17 , 19 , 22 – 26 , 29 – 37 , 39 , 41 17 for the rs1800871 (-819 C/T) SNP, 4 – 7 , 19 , 22 ,…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Dhaouadi,

Riahi,

Ben Abdallah

et al. 2024

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The impact of interleukin-10 (IL-10) gene promoter polymorphisms (SNPs) on treatment response in HCV patients was dissimilarly estimated. Hence, the aim of this meta-analysis was to robustly assess the effect of IL-10 SNPs on treatment response in HCV patients. An electronic literature search was carried out through PubMed, EMBASE, Web of science, and Scopus databases. Studies assessing the association between IL-10 polymorphisms and treatment response in HCV patients were included. Studies were excluded if genotype frequencies are not consistent with the Hardy–Weinberg Equilibrium (HWE) or in case of including patients with hepatitis B virus coinfection. Risk of bias in included studies was assessed using the Newcastle–Ottawa Scale. Meta-analyses were performed for the influence of IL-10 gene promoter SNPs (rs1800896 (-1082 A/G), rs1800871 (-819 C/T), and rs1800872 (-592 C/T)) and haplotypes on treatment response in HCV patients. Subgroup analyses, meta-regressions, publication bias assessment, and sensitivity analyses were also conducted. Overall, 32 studies with a total of 5943 HCV cases and 2697 controls were included in the present study. The -1082*G allele was significantly associated with increased risk of non-response (NR) to treatment, OR [95% CI] = 1.29 [1.1–1.51], p = .002. Besides, the rs1800872 -592*C allele was significantly associated with increased NR risk, OR [95% CI] = 1.22 [1.02–1.46], p = .03. Subgroup analysis showed that this association remained significant only in patients treated with PEG-IFN alone, p = .01. The -1082*G/-819*C/-592*C (GCC) haplotype was significantly associated with increased NR risk, OR [95% CI] = 1.62 [1.13–2.23], p = .009. Our results suggest that the IL-10 rs1800896 was associated with NR risk especially in North-African and Asian populations. Moreover, the IL-10 gene promoter -1082*G/-819*C/-592*C (GCC) haplotype which has been associated with higher production of IL-10, was significantly associated with increased NR risk.

show abstract

Section: Resultsmentioning

confidence: 99%

“… 4 – 8 , 17 – 43 Included studies characteristics are summarized in Table 4 . Twenty-three studies were included for the rs1800896 (-1082 A/G) SNP, 4 – 8 , 17 , 19 , 22 – 26 , 29 – 37 , 39 , 41 17 for the rs1800871 (-819 C/T) SNP, 4 – 7 , 19 , 22 , 27 , 30 …”

Section: Resultsmentioning

confidence: 99%

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Dhaouadi,

Riahi,

Ben Abdallah

et al. 2024

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Although some studies have reported a significant association between TNF polymorphism and response to hepatitis C treatment, some studies reported (24) from Taiwan suggested that TNF polymorphism at position-308 may be a predictor of treatment failure in patients treated with a combination of IFN-α and RBV and in another study from Brazil, the TNF-α-308 a allele was found to be a predictor of null virological response (25,26), but other investigations have failed to confirm such findings. An Egyptian study found that at the TNF-α 308 position, the G/G allele was most common (78.5%) in the study population compared to controls (27).…”

Section: Discussionmentioning

confidence: 99%

TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C

Günal¹,

Yalçin²,

Çelik³

et al. 2017

vhd

View full text Add to dashboard Cite

ÖZObjective: We aimed to review the influence of host genetic factors on the clinical course, treatment response as well as fibrosis progression in patients with viral hepatitis C genotype 1. Materials and Methods: Ninety-five patients with chronic hepatitis C virus (HCV) infection and 97 controls were enrolled. The patients received pegylated interferon (Peg-IFN)+ribavirin therapy for 48 weeks and were followed up for the next 48 weeks. Aspartat aminotransferase/platelet ratio (APRI) was used to detect liver fibrosis DNA specimens were extracted from the peripheral blood mononuclear cells and the tumor necrosis factor-alpha (TNF-α) 308 rs3091256 was genotyped by the polymerase chain reactionrestriction fragment length polymorphism method. Results: All patients included in the study were infected with HCV genotype 1. of the 95 HCV-positive patients, spontaneous viral clearence was observed in 25.5%, rapid viral response in 44.2%, early viral response in 91.8%, and sustained viral response was found in 73.3% of patients. The allele and genotype were not significant between patients and controls. There was no significant difference in virologic response as well. However, TNF-α-308 single nucleotide polymorphisms (SNP) rs3091256 GG genotype was strongly associated with fibrosis and alanine aminotransferase (ALT) levels (p=0.006 and p=0.017, respectively). Conclusion: TNF-α-308 polymorphisms may reveal different results among countries. Patients having SNP rs3091256 GG are prone to have higher ALT levels and fibrosis score but have better treatment outcome.

show abstract

“…Several studies show opposite results concerning the role of TNF-α rs1800629 in the natural course and antiviral therapy for chronic hepatitis C [ 25 – 27 ]. The results show the absence of any TNF-α-308G/A influence on the natural course and treatment outcome of chronic hepatitis C and suggest a modification of HCC development risk [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype

Danilau

Литвинчук

Solovey

et al. 2017

ceh

View full text Add to dashboard Cite

Aim of the studyTo evaluate the role of potential genetic predictors –308G/A TNF-α and –403G/A CCL5 in treatment for HCV 1 genotype.Material and methodsTreatment results of 130 patients with chronic hepatitis C 1 genotype according to different genotypes of IL28B, CCL5, and TNF-α were analysed using multiple logistic regression.ResultsIL28B genotypes CC/CT/TT were found in 27 (20.8%), 74 (56.9%), and 29 (22.3%) patients. Genotypes GG/GA/AA of –308G/A TNF-α were revealed in 98 (75.4%), 30 (23.1%), and 2 (1.5%) patients. Genotypes GG/GA/AA of –403G/A CCL5 were revealed in 86 (66.2%), 39 (30%), and 5 (3.8%) patients, respectively. The previously known effect of IL28B was observed. IL28B TT genotype decreased end of treatment response (EOTR) rates by a factor of 29.0 (95% CI: 6.4-183). The combination of CCL5 GG and IL28B CT genotypes increased the risk of failure to achieve EOTR by a factor of 28.5 (95% CI: 7.2-160). Genotypes GA and AA of TNF-α (–308) G/A SNP increased the risk of relapse in patients who achieved EOTR (OR = 9.4; 95% CI: 2.4-48).ConclusionsPractitioners may benefit from using these predictors when considering indications for the antiviral therapy and deciding on the treatment regimen.

show abstract

Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients

Cited by 7 publications

References 40 publications

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C

Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype

Contact Info

Product

Resources

About